title: Rapid ventricular tachycardias associated with cilostazol use.
abstract: A 92-year-old woman with normal systolic function had recently begun using the newly approved phosphodiesterase III inhibitor cilostazol when she was admitted with lower-extremity pain. Cilostazol is indicated for patients with intermittent claudication and contraindicated for patients with congestive heart failure. Two days after admission, the patient developed ventricular tachycardia. Cilostazol was discontinued, and shortly thereafter the ventricular tachycardia subsided. In this case, cilostazol was apparently an important predisposing factor for ventricular tachycardia.
authors.affiliation: Texas Heart Institute at St. Luke's Episcopal Hospital, Houston 77030, USA.
authors.forename: Farhad
authors.initials: F
authors.lastname: Gamssari
authors.forename: Hatim
authors.initials: H
authors.lastname: Mahmood
authors.forename: John S
authors.initials: JS
authors.lastname: Ho
authors.forename: Rollo P
authors.initials: RP
authors.lastname: Villareal
authors.forename: Brant
authors.initials: B
authors.lastname: Liu
authors.forename: Abdi
authors.initials: A
authors.lastname: Rasekh
authors.forename: Efrain
authors.initials: E
authors.lastname: Garcia
authors.forename: Ali
authors.initials: A
authors.lastname: Massumi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077407:Cilostazol; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D017180:Tachycardia, Ventricular / Q000139:chemically induced*; D013777:Tetrazoles / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000009:adverse effects*
chemical_list: D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol